FAB Pharma, a Biopharma Company Developing Drugs to Treat Severe Bacterial Infections, Raises €2.3 Million in Series A Funding and Begins Recruitment for a Phase I Trial of Its Lead Compound

Published: Sep 14, 2009

PARIS--(BUSINESS WIRE)--FAB Pharma today announced the completion of a €2.3 million round of series A funding led by CDC innovation and co-led by Bioam Gestion.

Back to news